International Journal of Pancreatology

, Volume 5, Issue 2, pp 179–189 | Cite as

Dose-dependent inhibition by cyclosporine a of the induction of pancreatic ornithine decarboxylase (ODC) in rats

  • Christian Löser
  • Fritz Stöckmann
  • Ulrich R. Fälsch
  • Werner Creutzfeldt


The effect of cyclosporine A (CsA) and α-difluoromethylornithine (DFMO) on the camostate-induced increase in pancreatic ornithine decarboxylase (ODC) activity and polyamine biosynthesis has been studied in vivo. Six hours after application of the synthetic trypsin inhibitor camostate (200 mg/kg b wt orally) pancreatic ODC activity increased about 140-fold and putrescine concentration about ninefold. CsA inhibited the elevation of both parameters in a dose-dependent manner. CsA pretreatment for 3 d with doses of 7.5, 10.0, and 12.5 mg/kg b wt orally once a day and consecutive CsA blood levels 24 h after the last CsA application of 751 ±62, 968 ±70, and 1,395 ±79 ng/mL, respectively, resulted in a complete inhibition of the camostate-stimulated increase in pancreatic ODC activity and putrescine concentration in vivo. DFMO (2% in drinking water and additionally 300 mg/kg b wt intraperitoneally at 8 AM, 12 noon, and 4 PM) inhibited the increase in both, ODC activity, and putrescine, significantly in an equipotent degree as 2.5 mg CsA/kg b wt, whereas higher doses of CsA proved to be more effective than DFMO in the chosen subtoxic dose. In all cases, no significant changes in pancreatic spermidine and spermine concentration, DNA and protein content, or pancreatic and body weight were observed. It is concluded that CsA in doses used for immunosuppression in clinical practice is a very potent and more effective inhibitor of ODC activity and polyamine synthesis in vivo than DFMO. This ODC inhibitory effect of CsA is a further detail to elucidate the up to now incompletely understood mechanisms of action of this immunosuppressive agent.

Key Words

Cyclosporine A α-difluoromethylornithine ornithine decarboxylase polyamines pancreatic growth camostate 



cyclosporine A




ornithine decarboxylase




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Borei JF. Cyclosporine: Historical perspectives. Transplant. Proc. 1983; 15: 2219–2229.Google Scholar
  2. 2.
    Cohen JD, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann. Int. Med. 1984; 101: 667–682.PubMedGoogle Scholar
  3. 3.
    Pegg AE, McCann PP. Polyamine metabolism and function. Am. J. Physiol. 1982; 243: 212–221.Google Scholar
  4. 4.
    Tabor CW, Tabor H. Polyamines, Ann. Rev. Biochem. 1984; 53: 749–790.PubMedCrossRefGoogle Scholar
  5. 5.
    Morisset J, Benrezzak O. Polyamines and pancreatic growth induced by caerulein. Life Sci. 1984; 35: 2471–2480.PubMedCrossRefGoogle Scholar
  6. 6.
    Löser Chr, Fölsch UR, Mustroph D, Cantor P, Wunderlich U, Creutzfeldt W. Pancreatic polyamine concentrations and cholecystokinin plasma levels in rats after feeding raw or heat-inactivated soybean flour. Pancreas 1988; 3: 285–291.PubMedCrossRefGoogle Scholar
  7. 7.
    Russell DH. Ornithine decarboxylase: A key regulatory enzyme in normal and neoplastic growth, Drug Metab. Rev. 1985; 16: 1–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Russell DH. Ornithine decarboxylase as a biological and pharmacological tool, Pharmacology 1980; 20: 117–129.PubMedCrossRefGoogle Scholar
  9. 9.
    Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. by substrate and product, analogues. J. Am. Chem. Soc. 1978; 100: 2551–2553.CrossRefGoogle Scholar
  10. 10.
    Fidelus RK, Laughter AH, Twomey JJ, Taffet SM, Haddox MK. The effect of cyclo-sporine on ornithine decarboxylase induction with mitogens, antigens, and lymphokines. Transplantation 1984; 37: 383–387.PubMedCrossRefGoogle Scholar
  11. 11.
    Saydjari R, Townsend CM, Barranco SC, James E, Thompson JC. Effects of cyclosporin A and α-difluoromethylornithine on the growth of hamster pancreatic cancer in vitro. J.N.C.I. 1986; 77: 1087–1092.Google Scholar
  12. 12.
    Saydjari R, Townsend CM, Barranco SC, Thompson JC. Effects of cyclosporine and α-difluoromethylornithine on the growth of mouse colon cancer in vitro. Life Sci. 1987; 40: 359–366.PubMedCrossRefGoogle Scholar
  13. 13.
    Russell DH, Larson DF, Cardon SB, Copeland JG. Cyclosporine inhibits prolactin induc- tion of ornithine decarboxylase in rat tissues. Mol. Cell. Endocrinol. 1984; 35: 159–166.PubMedCrossRefGoogle Scholar
  14. 14.
    Russell DH, Larson DF. Prolactin-induced polyamine biosynthesis in spleen and thymus: Specific inhibition by cyclosporine. Immunopharmacol. 1985; 9: 165–174.CrossRefGoogle Scholar
  15. 15.
    Göke B, Printz H, Koop I, Rausch U, Richter G, Arnold R. Endogenous CCK release and pancreatic growth in rats after feeding a proteinase inhibitor (camostate). Pancreas 1986; 1: 509–515.PubMedCrossRefGoogle Scholar
  16. 16.
    Wisner JR, McLaughlin RE, Rich KA, Ozawa S, Renner IG. Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas. Gastroenterology 1988; 94: 109–113.PubMedGoogle Scholar
  17. 17.
    Caldwell KA. Induction of ornithine decarboxylase activity in weanling rat pancreas by an orally administered soy protein isolate. Toxicol. Appl. Pharmacol. 1987; 87: 483–489.PubMedCrossRefGoogle Scholar
  18. 18.
    Donatsch P, Abisch E, Hornberger M, Traber R, Trapp M, Voges R. A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J. Immunoassay 1981; 2: 19–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Löser Chr, Wunderlich U, Fölsch UR. Reversed phase liquid chromatographic separation and simultaneous fluorimetric detection of polyamines and their monoacetyl derivatives in human and animal urine, serum and tissue samples—An improved, rapid and sensitive method for routine application. J. Chromatogr. 1988; 430: 249–262.PubMedCrossRefGoogle Scholar
  20. 20.
    Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 1980; 102: 344–352.PubMedCrossRefGoogle Scholar
  21. 21.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248–255.PubMedCrossRefGoogle Scholar
  22. 22.
    Russell DH, Buckley AR, Montgomery DW, Larson NA, Gout PW, Beer CT, Putnam CW, Zukoski CF, Kibler R. Prolactin-dependent mitogenesis in Nb 2 node lymphoma cells: effects of immunosuppressive cyclopeptides. J. Immunol. 1987; 138: 276–284.PubMedGoogle Scholar
  23. 23.
    Fidelus RK, Laughter AH. Protein kinase activation and the immunosuppressant cyclosporine. Transplantation 1986; 41: 187–192.PubMedCrossRefGoogle Scholar
  24. 24.
    Larson DF. Mechanism of action: Antagonism of the prolactin receptor. Prog. Allergy 1986; 38: 222–238.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1989

Authors and Affiliations

  • Christian Löser
    • 1
  • Fritz Stöckmann
    • 1
  • Ulrich R. Fälsch
    • 1
  • Werner Creutzfeldt
    • 1
  1. 1.Div. of Gastroenterology and Endocrinology, Dept. of MedicineGeorg-August-University of GöttingenGöttingenFRG

Personalised recommendations